Thalidomide and rituximab in Waldenstrom macroglobulinemia.

Blood
Steven P TreonKenneth C Anderson

Abstract

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m(2) per week) dosed on weeks 2 to 5 and 13 to 16. Twenty-five patients were enrolled, 20 of whom were untreated. Responses were complete response (n = 1), partial response (n = 15), and major response (n = 2), for overall and major response rate of 72% and 64%, respectively, on an intent-to-treat basis. Median serum IgM decreased from 3670 to 1590 mg/dL (P < .001), whereas median hematocrit rose from 33.0% to 37.6% (P = .004) at best response. Median time to progression for responders was 38 months. Peripheral neuropathy to thalidomide was the most common adverse event. Among 11 patients experiencing grade 2 or greater neuropathy, 10 resolved to grade 1 or less at a median of 6.7 months. Thalidomide in combination with rituximab is active and produces long-term responses in WM. Lower doses of thalidomide (ie, <or= 200 mg/day) should be considered given the high frequency of ...Continue Reading

Associated Clinical Trials

Sep 2, 2005·Steven P. Treon, MD, PhD, Steven P. Treon, MD, PhD

References

Jan 22, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J C ByrdA J Grillo-López
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosP Panayiotidis
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos
Apr 30, 2003·Seminars in Oncology·Jerome B ZeldisDavid I Stirling
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William Larry GluckMaurice Wolin
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonK C Anderson
Dec 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonUNKNOWN Waldenström's Macroglobulinemia Clinical Trials Group
Jan 11, 2005·British Journal of Haematology·Toshiaki HayashiKenneth C Anderson
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonEdward A Fox
Mar 30, 2005·Clinical Lymphoma·Meletios A DimopoulosGerrassimos Pangalis
Mar 30, 2005·Clinical Lymphoma·Steven P TreonAndrew R Barnagan
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Khuda D KhanMichael A Caligiuri
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios Athanasios DimopoulosGerasimos Pangalis
Oct 13, 2007·Clinical Lymphoma & Myeloma·Steven P TreonIrene Ghobrial
May 1, 1998·Analytical Chemistry

❮ Previous
Next ❯

Citations

Jan 29, 2011·Cancer Metastasis Reviews·Roch HouotRonald Levy
Jul 17, 2013·Frontiers of Medicine·Miao XuJun Peng
Jun 19, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Lucy S Hodge, Stephen M Ansell
Feb 7, 2013·Leukemia·C Buske, V Leblond
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Apr 27, 2011·Current Opinion in Hematology·Ghayas C IssaIrene M Ghobrial
Jul 21, 2009·Blood·Steven P Treon
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonIrene M Ghobrial
Oct 29, 2011·Clinical Investigation·Ghayas C IssaAldo M Roccaro
Apr 26, 2014·Immunotherapy·Laetitia Souchet-CömpainStéphanie Nguyen
Sep 13, 2014·Hematology/oncology Clinics of North America·Steven P TreonGiampaolo Merlini
Sep 25, 2010·Hematology·Vassiliki Saloura, Petros D Grivas
Nov 20, 2008·Current Treatment Options in Oncology·Peter H Wiernik
Aug 7, 2012·Leukemia & Lymphoma·Morie Gertz
Jul 22, 2015·Expert Review of Anticancer Therapy·Rajshekhar ChakrabortyMorie A Gertz
Jan 11, 2014·Expert Review of Hematology·Ilyas SahinIrene M Ghobrial
Mar 23, 2011·Expert Review of Anticancer Therapy·Ahmad S Halwani, Brian K Link
Nov 19, 2010·Expert Review of Hematology·Jennifer StedmanIrene M Ghobrial
Jul 4, 2015·Expert Review of Hematology·Rajshekhar ChakrabortyMorie A Gertz
Feb 14, 2012·Expert Opinion on Pharmacotherapy·Sonia ValletKlaus Podar
Nov 19, 2010·Expert Review of Hematology·Ramón García-Sanz, Enrique M Ocio
Mar 1, 2011·Expert Opinion on Emerging Drugs·Efstathios KastritisMeletios A Dimopoulos
Sep 11, 2010·Expert Opinion on Emerging Drugs·Jack D Burton, David M Goldenberg
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosI M Ghobrial
Apr 7, 2010·La Revue de médecine interne·S PoulainX Leleu
Apr 14, 2009·Clinical Lymphoma & Myeloma·Evangelos TerposMeletios-Athanassios Dimopoulos
Apr 14, 2009·Clinical Lymphoma & Myeloma·Meletios A DimopoulosEvangelos Terpos
Apr 14, 2009·Clinical Lymphoma & Myeloma·Leukothea IoakimidisSteven P Treon
Dec 18, 2008·European Journal of Haematology·Xavier LeleuIrene M Ghobrial
May 9, 2013·British Journal of Haematology·Anita D'SouzaMorie A Gertz
Aug 19, 2015·American Journal of Hematology·Guillemette FouquetXavier Leleu
Apr 22, 2011·American Journal of Hematology·Efstathios KastritisMeletios A Dimopoulos
Feb 18, 2014·British Journal of Haematology·Roger G OwenUNKNOWN British Committee for Standards in Haematology
Apr 18, 2015·Blood Reviews·Prashant KapoorPhilip R Greipp
Oct 23, 2012·Clinical Lymphoma, Myeloma & Leukemia·Steven P TreonZachary R Hunter
Dec 7, 2013·Clinical Lymphoma, Myeloma & Leukemia·Houry LeblebjianIrene Ghobrial
Apr 8, 2010·Clinical Lymphoma, Myeloma & Leukemia·Meletios A DimopoulosSteven P Treon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Steven P TreonKenneth C Anderson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Meletios A DimopoulosGerasimos Pangalis
© 2022 Meta ULC. All rights reserved